PIK3CA-Related Overgrowth Spectrum clinical trials at UCSF

1 research study open to eligible people

PIK3CA-related overgrowth spectrum leads to abnormal body growth. UCSF is evaluating the safety and effectiveness of Alpelisib for people with this condition. The trial involves multiple centers and runs for 16 weeks.

Showing trials for

  • PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

    open to eligible people ages up to 100 years

    This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

    San Francisco, California and other locations

Our lead scientists for PIK3CA-Related Overgrowth Spectrum research studies include .

Last updated: